Abcam plc Annual Report and Accounts 2017 Sustaining   long-term growth Abcam plc Annual Report and Accounts 2017 Investing for a  sustainable future We are committed to serving life science researchers to  achieve their mission faster. We continue to identify the  biological pathways of greatest interest to our consumers   and continuously strive to provide products of the highest  quality with increased specificity, reproducibility and sensitivity. At the same time, through investment and acquisition, we  are expanding into new markets, identifying new technologies  and applications while moving into new geographic regions,  thereby driving sustainable growth. Strategic report Mission To serve life scientists to   achieve their mission faster Vision To be the most influential life sciences  company for researchers worldwide Strategic report 1 Highlights of our year 2 About us 4 Chairman’s introduction 6 Our business model 7	 Chief	Executive	Officer’s	review 10 Our markets 12 Our strategic priorities 14 Our KPIs 15 Our risks 20  Sustainability 22	 Our	financials Corporate governance 29	 Chairman’s	governance	overview 30  Directors and Company Secretary 32  Corporate governance report 37 Audit and Risk Committee 40 Nomination Committee 41 Remuneration report 55 Directors’ report Financial statements 59 Independent auditors’ report 65 Consolidated income statement 65  Consolidated statement of comprehensive income 66 Consolidated balance sheet 67 Consolidated statement of changes in equity 68	 Consolidated	cash	flow	statement 69	 Notes	to	the	financial	statements 97 Company balance sheet 98 Company statement of changes in equity 99	 Notes	to	the	Company	financial	statements 107 Technical glossary 108 Corporate directory 108 Shareholder information Financial highlights •  Total revenue increased 26.5% on a reported basis to   £217.1m (FY 2016: £171.7m). On a constant exchange rate  (CER) 1 	 basis 	 the 	 increase 	 was 	 9.9% 2 , meeting our full year guidance •  Catalogue revenue increased by 27.4% on a reported basis  to £202.5m (FY 2016: £159.0m) and 10.8% on a CER basis •  RabMAb ®  primary antibody and non-primary antibody  revenues	grew	on	a	reported	basis	by	43.9%	and	33.0%,	 and 25.2% and 15.6% on a CER basis, respectively, both  delivering on our key performance indicator (KPI) targets • 	 Reported	gross	margin	of	70.1%	following	the	reclassification	 of certain costs 3  (FY 2016: 70.2%). On a like for like basis FY 2016  gross	margin	was	69.2% • EBITDA	margin	was	32.5%	(FY	2016:	33.6%). Adjusted	EBITDA	 margin 4 	was	33.8%	(FY	2016:	34.9%),	reflecting	the	continued	 investment in the business • Profit	before	tax	(PBT)	on	a	reported	basis	was	£51.9m	 (FY 2016: £45.4m) and £64.6m (FY 2016: £53.8m) on an  adjusted	basis 5 •  Reported diluted earnings per share (EPS) increased by 11.9%  to	20.74	pence	(FY	2016:	18.53	pence). Adjusted	diluted	EPS 6   increased by 13.9% to 25.46 pence (FY 2016: 22.35 pence) • 	 Closing	cash	and	cash	equivalents	and	term	deposits	were	 £84.8m (30 June 2016: £70.7m) •  Proposed full year dividend increase of 14% to 10.18 pence  per share (FY 2016: 8.91 pence) Operational highlights •  Continued to gain market share globally as a result of our  direct customer focus and digital marketing leadership  •  Led stakeholder discussions to raise industry quality standards  through knockout validation, expansion of recombinant  antibody portfolio, and other quality initiatives  •  Expanded use of the FirePlex ®  (formerly Firefly ® )	platform	within	 the kits/assays range by introducing 142 validated antibody pairs  and validated a range of these pairs in multiplex immunoassays •  Further expanded our addressable market in custom  products and licensing by providing ‘Abcam Inside’ for multiple  pharmaceutical and diagnostic development partners  •  Accelerated AxioMx technology milestone payments in  recognition	of	technical	success	demonstrated	with	the	 unique antibody development capabilities at AxioMx •  Launched several of the Oracle Cloud modules of our  new	ERP	system	and	made	good	progress	towards	 full implementation in FY 2018 •  Completed recruitment of the Executive Leadership Team  with	the	appointment	of	a	new	CFO	as	well	as	new	hires	 of Senior VP of Technology and Senior VP of Global  Manufacturing & Supply Chain •  Commissioned construction of Abcam’s purpose-built global  HQ at the expanding Biomedical Campus in Cambridge, UK,  with	expected	occupancy	in	FY	2019 1   Constant currency is calculated by applying prior period’s actual exchange  rates to this period’s results. 2	 	 Unaudited	figures	 in	our	pre-close	updat e	stated	10.2%	revenue	growth. As	a	 result 	 of 	 the 	 completion 	 of 	 the 	 year-end 	 financial 	 review 	 and 	 audit, 	 actual 	 total	 revenue	growth	in	the	year	is	9.9%..